Weronika Stupalkowska

Dr. Weronika Stupalkowska


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
WSWeronika Stupalkowska
Weronika Stupalkowska
SPSarah F. Powell-Brett
Sarah F. Powell-Brett
BKBrandon Krijgsman
Brandon Krijgsman
Grynfeltt-Leschaft hernia is a type of lumbar hernia occurring in the superior lumbar triangle. Because of its rarity and non-specific presentation, lumbar hernia often poses a diagnostic challenge, and it can be easily misdiagnosed as a lipoma. If the correct diagnosis is missed, there is a significant risk of complications including hernia incarceration or strangulation. Here, we present a case of Grynfeltt-Lesshaft hernia which was repeatedly misdiagnosed as a lipoma and presented acutely with large bowel obstruction. A definite diagnosis was made by a computed tomography scan and the patient had emergency laparotomy and successful mesh repair of the hernia defect.

30 September 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
WSWeronika Stupalkowska
Weronika Stupalkowska
AHAlexander Henney
Alexander Henney
ESEric G. Sheu
Eric G. Sheu
UAUazman Alam
Uazman Alam
DCDaniel J. Cuthbertson
Daniel J. Cuthbertson
Aim: Metabolic bariatric surgery (MBS) improves histological endpoints in steatotic liver disease (SLD), but data on longer‐term clinical outcomes in this population are scarce. Here, we assessed the impact of MBS on hepatic and extrahepatic morbidity and mortality in individuals with SLD. Methods: Patients with SLD, with/without a history of MBS (MBS/no‐MBS cohorts, respectively) between 01/01/2004 and 31/10/2019, were identified using the TriNetX platform. Cohorts were balanced with propensity score matching (PSM). Maximum follow‐up was set to 5 years. The primary outcome was a composite of major adverse liver outcomes (MALO): cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant. Secondary outcomes included major cardiovascular (MACE) and kidney (MAKE) adverse events, obesity‐associated cancers, and all‐cause mortality (ACM). We performed sub‐group analyses according to sex, MBS type, and risk factors (BMI ≥50 kg/m 2 and type 2 diabetes (T2D)). Results: We identified 15,262 and 540,031 patients (for the MBS and no‐MBS cohorts, respectively); 14,970 patients/cohort after PSM (mean age: 46.7 vs. 47.4; female: 74.3% vs. 75.7%; mean follow‐up, 4.1 years). MBS was associated with reduced HR of MALO (0.84, 95% CI 0.75–0.95), MACE (0.52, CI 0.47–0.57), MAKE (0.54, CI 0.41–0.72), obesity‐related cancers (0.58, CI 0.50–0.67), and ACM (0.49, 0.43–0.56). In subgroup analyses, MBS was associated with reduced HR of MALO, MACE, MAKE, obesity‐related cancers, and ACM in females, patients with T2D, BMI > 50 kg/m 2 and irrespective of surgery type. Conclusion: In patients with SLD, MBS is associated with significant reductions in the rates of adverse hepatic and extrahepatic outcomes and all‐cause mortality over 4 years' follow‐up.

5 January 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
WSWeronika Stupalkowska
Weronika Stupalkowska
BMBetania Mahler-Araujo
Betania Mahler-Araujo
JBJohn Bennett
John Bennett
SGStavros Gourgiotis
Stavros Gourgiotis
Here we present a rare case of spontaneous colonic perforation in a middle-aged woman affected by systemic sclerosis (SSc). In spite of maximal medical support and prompt emergency laparotomy for source control the patient died due to multiorgan failure within 48 hours of admission. This case emphasises that although rarely, patients with scleroderma can present with colonic perforation which unfortunately due to their decreased physiological reserve, can lead to rapid and irreversible deterioration and subsequent death. It is therefore essential that clinicians faced with abdominal symptoms and signs in patients affected by SSc are able to quickly differentiate acute visceral perforation from benign causes.

1 March 2020 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
ZAZeeshan Afzal
Zeeshan Afzal
WSWeronika Stupalkowska
Weronika Stupalkowska
MMMaria B Mahler-Araujo
Maria B Mahler-Araujo
DBDavid Bowden
David Bowden
RDRichard J Davies
Richard J Davies
Primary retroperitoneal mucinous cystadenoma (PRMC) is a rare tumour. It was first reported in 1965, and since then, less than 100 cases have been reported. It is cystic in nature and most commonly affects the female population. It becomes symptomatic in later stages due to its mass effect, making the diagnosis challenging in its early asymptomatic stage. We report a case of a 32-year-old female who presented with abdominal pain and a mass in left iliac fossa. Diagnostic imaging revealed a large cystic lesion in retroperitoneum. A midline laparotomy was performed, and a complete surgical excision was accomplished without any spillage. Surgical histology confirmed the diagnosis of PRMC. The patient was discharged on postoperative day 2. There was no evidence of tumour recurrence on repeat imaging at 90-day follow-up. Surgical approach, with complete resection and without any spillage, remains the most effective and appropriate treatment for this tumour.

1 September 2020 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PTPaul Traynor
Paul Traynor
WSWeronika Stupalkowska
Weronika Stupalkowska
TMTahira Mohamed
Tahira Mohamed
EGEdmund Godfrey
Edmund Godfrey
JBJohn M H Bennett
John M H Bennett
SGStavros Gourgiotis
Stavros Gourgiotis
Intestinal perforation following the ingestion of fishbone is unusual and rarely diagnosed preoperatively, as clinical and radiological findings are non-specific. We report a case of a female patient post Roux-en-Y gastric bypass (RYGBP) for obesity, who presented with severe abdominal pain and guarding in left iliac fossa. Computed tomography (CT) suggested internal herniation with compromised vascular supply to the bowel. Exploratory laparotomy identified a perforation site in the blind loop of the RYGBP due to a protruding fishbone. After extraction, primary suture repair was performed. In retrospect, the fishbone was identified on CT but misinterpreted as suture line at the enteroenterostomy site. This case emphasizes that although rare, the ingestion of fishbone can lead to severe complications and should therefore be included in the differential for an acute abdomen. On CT, it should be noted that fishbone may simulate suture line within the bowel if the patient has history of previous surgery.

13 April 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
WSWeronika Stupalkowska
Weronika Stupalkowska
AHAlex E. Henney
Alex E. Henney
DRDavid R. Riley
David R. Riley
ESEric G Sheu
Eric G Sheu
UAUazman Alam
Uazman Alam
DCDaniel J. Cuthbertson
Daniel J. Cuthbertson
Aim: We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods: Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database). The primary outcome was a composite of major adverse liver outcomes (MALO): decompensation events or liver transplant. Secondary outcomes included a composite of major adverse cardiovascular events (MACE), first diagnosis of cirrhosis, heart failure, or obesity‐associated cancer (OAC), and all‐cause mortality (ACM). Subgroup analyses were performed for Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Results: MBS, compared with semaglutide, was associated with a higher hazard rate (HR) of MALO (HR 1.63; 95% CI 1.12–2.37); this was driven by RYGB (2.01; 1.26–3.20) but not by SG (0.97; 0.52–1.78). However, after excluding patients with pre‐existing cirrhosis, MBS was associated with a reduced HR of new cirrhosis (0.46; 0.29–0.73). For extrahepatic events, MBS was associated with a reduced HR of MACE (0.51; 0.38–0.67), heart failure (0.41; 0.27–0.62), and OAC (0.56; 0.34–0.92). There was no difference in ACM between MBS and semaglutide, but in subgroup analysis, RYGB was associated with increased ACM compared to semaglutide (1.64; 1.01–2.67). Conclusion: In patients with MASLD and T2D, MBS, and specifically RYGB, as compared to semaglutide, may drive a relatively increased risk of MALO despite protection against MACE, the first diagnosis of cirrhosis, heart failure, and OAC. Liver evaluation in individuals with T2D referred for MBS may help optimize their treatment.